Biocon is one of the largest insulin's producer in Asia and its rh-Insulin today, has marketing approvals in 60 countries & over 20 countries for Insulin Glargine. As on 25th Aug. 2016, European Medicines Agency (EMA) has accepted to review Mylan and Biocon's application for a biosimilar called Trastuzumab, used for certain breast and gastric cancers. Marketing approval for the drug is likely to come in next 12-18 months having an addressable market close to USD 7 billion, which opens up a huge opportunity for Biocon and Mylan both. This is the second biosimilar submission developed by partnership that has been accepted for review in Europe. Last month, Mylan's...